Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2013

View Archived Issues

A proof of principle study of a predictive biomarker-based blood test for suicide risk

Preclinical validation of a first-in-class p53 pathway reactivator for the treatment of cancer

Demonstration of an effective cure for symptomatic Ebola virus infection

Lumena begins patient recruitment for CLARITY and IMAGO

New FSH-R agonists discovered by Merck KGaA

Novel TLR7/TLR8 receptor agonists disclosed by Janssen R&D Ireland

Researchers at Lupin synthesize new agents for HCV infection

Chinese researchers prepare novel tyrosine-protein kinase inhibitors

New P2X receptor antagonists described by Shionogi & Co.

New adenoviral vector with enhanced immunogenicity against HCV

ReNeuron's retinal stem cell therapy receives orphan drug status

Sanofi Pasteur reports topline data for Fluzone High-Dose vaccine

CP-9531 shows promising efficacy and safety in vivo

KemPharm reports data from KP-201 study

Alcobra enrolls first patient in predominantly inattentive ADHD study

Ultragenyx Pharmaceutical's triheptanoin IND is now active

Oragenics reports data from lantibiotics program

Japan's MHLW Drug Committee endorses QVA-149 approval

FDA approves first topical therapy for erythema in patients with rosacea

Takeda and Zinfandel begin phase III trial to delay MCI in Alzheimer's disease

Rigel to discontinue R-343 development

FDA grants priority review to Nexavar sNDA in RAI-refractory differentiated thyroid cancer

Sangamo BioSciences signs definitive agreement to acquire Ceregene

Lipidor's phase I/II trial of Akvano/calcipotriol spray meets primary endpoint